Avalon Pharmaceuticals Inc (NASDAQ:AVRX) to Hold Q2 2008 Earnings Conference Call August 13

Avalon Pharmaceuticals, Inc (NASDAQ:AVRX) will hold a conference call on Wednesday, August 13 at 1:00 pm ET to discuss the financial results for the second quarter of 2008.  Interested parties may hear the call by dialing 877-548-7913 or 719-325-4932 for callers outside of the United States.  A webcast of the presentation will also be available on the Investor Relations section of the company’s website at avalonrx.com.

Avalon Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of first-in-class cancer therapeutics. Its lead product candidate, AVN944, an inosine monophosphate dehydrogenase (IMPDH) inhibitor, is in Phase II clinical development.

The Company has preclinical programs to develop inhibitors of the Beta β-catenin and Aurora/Centrosome pathways, discovery programs for inhibitors of the Survivin and Myc pathways, and partnerships with Merck, AstraZeneca, ChemDiv, Medarex and Novartis. Avalon Pharmaceuticals uses AvalonRx, its platform based on large-scale biomarker identification and monitoring, to discover and develop therapeutics for pathways that have been characterized as undruggable.

Read more Business News on The Global Market Directory.

About The Global Market Directory (TheGMD)

TheGMD provides an online global directory listing featuring public companies, stock brokers, brokerage firms and individuals.  The GMD provides profiles for Brokerage Firms, Stock Brokers and Individuals in addition to Public Companies.

The GMD is a division of TransWorldNews, Inc. Companies can utilize the TransWorldNews press release distribution services and have all news releases attached to their GMD profile.

Create your profile on The Global Market Directory.